Celldex Therapeutics
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 2 months.
- Its last 4 Sell calls were followed by a 8% average decline over the next quarter.
- Recent price momentum is -11.0% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Short interest has risen to 12.7% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 02:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability D+
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 100.0% | Better than 99% |
| Operating margin | -18,599.8% | Better than 0% |
| Net margin | -16,748.0% | Better than 1% |
| Return on equity | -40.6% | Better than 10% |
| Return on invested capital | -40.4% | Better than 8% |
Momentum C
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -32.1% | Better than 16% |
| 6-month return | -10.8% | Better than 39% |
| 12-month return (ex latest month) | 12.8% | Better than 51% |
| Distance below 52-week high | 39.3% | Better than 29% |
Financial Health A-
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 10.5x | Better than 94% |
| Debt to assets | 0.4% | Better than 96% |
| Interest coverage | -87.0x | Better than 5% |
Analyst View A
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 90.9% | Better than 74% |
| Upside to average target | 145.0% | Better than 90% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 27.96
- Open
- 27.01
- Day range
- 26.64 - 28.43
- Avg price
- 27.45
- Volume
- 1.72M
- Turnover
- 47.10M
- Turnover ratei
- 2.34%
- Volume ratioi
- 2.75
- Amplitudei
- 6.38%
- 52-week rangei
- 22.33 - 45.14
Valuation
- P/Ei
- -7.03
- P/E (TTM)i
- -6.39
- P/Bi
- 3.32
- EPSi
- -3.90
- Book value / shi
- 8.27
- Net profit
- -306.33M
- Net assets
- 649.49M
Share structure
- Market cap
- 2.15B
- Float capi
- 2.01B
- Shares out
- 78.55M
- Float sharesi
- 73.29M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
39.3% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+9.17M net over the window
Short interest
- Shares short
- 9.94M
- % of floati
- 12.65%
- Days to coveri
- 10.35
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Celldex Therapeutics (CLDX)?
Celldex Therapeutics last traded at 27.42. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Celldex Therapeutics's market cap?
About 2.15B.
What is the P/E ratio of Celldex Therapeutics?
The trailing twelve-month P/E is -6.39. The Valuation tab shows it against the stock's own five-year range.
Does Celldex Therapeutics pay a dividend?
Celldex Therapeutics does not currently pay a regular dividend.
Is Celldex Therapeutics a buy according to analysts?
The consensus of 11 analysts is a Buy rating, with an average 12-month price target of 67.18, which implies 145.0% upside from the current price. This is not investment advice.
What is Celldex Therapeutics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Celldex Therapeutics a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Celldex Therapeutics discussion 0 comments